The prognostic impact of net ultrafiltration intensity in critically ill patients receiving continuous renal replacement therapy: a multivariable and propensity-matched analysis

净超滤强度对接受连续性肾脏替代治疗的危重患者预后的影响:一项多变量倾向性匹配分析

阅读:1

Abstract

OBJECTIVES: Net ultrafiltration (UF(net)) is widely used for fluid management during continuous renal replacement therapy (CRRT) for critically ill patients over extended periods. Despite widespread use, the relationship between UF(net) intensity and clinical outcomes, particularly mortality, remains controversial. METHODS: This retrospective observational study examined critically ill patients undergoing CRRT for more than 72 h from January 2021 to September 2023. Patients were stratified by their UF(net) intensity during the initial 72 h of CRRT into low (<1.01 mL/kg/h), moderate (1.01-1.75 mL/kg/h), and high (>1.75 mL/kg/h) groups. The primary outcome was 28-day mortality. Kaplan-Meier's survival curves with log-rank tests, Cox proportional hazards models, and propensity score matching were employed to assess the association between UF(net) intensity and mortality. RESULTS: A total of 683 patients were included. Compared with the moderate UF(net) intensity, the low UF(net) intensity (adjusted hazard ratio (HR) 1.54, 95%CI 1.24-1.91, p = .024) and high UF(net) intensity (adjusted HR 1.27, 95%CI 1.03-1.57, p < .001) were associated with higher 28-day mortality. Sensitivity analyses showed similar trends for 60-day and 90-day mortality. Subgroup analyses based on admission diagnosis did not reveal significant differences in the effect of UF(net) intensity on mortality risk. CONCLUSIONS: UF(net) intensity between 1.01 and 1.75 mL/kg/h during the first 72 h of CRRT was associated with lower 28-day mortality compared to both lower and higher UF(net) intensities. However, future studies are needed to better define optimal UF(net) thresholds in multicenter ICU cohorts.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。